Abstract
The sulphydryl compound WR 2721 has been combined with a range of cytotoxic drugs in the mouse and the effects upon tumours and normal tissues determined. In the acute lethality (LD50/30) assay, mean protection factors produced by WR 2721 (200 or 400 mg kg-1) were generally less than 1.3 for cyclophosphamide (CTX), CCNU and chlorambucil (CHL) but a protection factor of 1.7 was obtained for cisplatinum (cis-P) in combination with 400 mg kg-1 of WR 2721. No protection against the depression of peripheral white cell count seen at 3 days after CTX, CCNU or cis-P was obtained with either 200 or 400 mg kg-1 of WR 2721. Significant protection of the RIF-1 sarcoma by WR 2721 against CTX and cis-P induced growth delay was seen. In the KHT sarcoma, WR 2721 produced small reductions in the growth delay caused by CCNU, melphalan and CHL but these were not statistically significant. These data show less differential normal tissue protection by WR 2721 than do a number of reports in the literature.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Clement J. J., Johnson R. K. Influence of WR 2721 on the efficacy of radiotherapy and chemotherapy of murine tumors. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):539–542. doi: 10.1016/0360-3016(82)90679-4. [DOI] [PubMed] [Google Scholar]
- Kallman R. F., Silini G., Van Putten L. M. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. J Natl Cancer Inst. 1967 Sep;39(3):539–549. [PubMed] [Google Scholar]
- Milas L., Hunter N., Reid B. O., Thames H. D., Jr Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice. Cancer Res. 1982 May;42(5):1888–1897. [PubMed] [Google Scholar]
- Rojas A., Stewart F. A., Denekamp J. Experimental radiotherapy with WR-2721 and misonidazole. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):527–530. doi: 10.1016/0360-3016(82)90676-9. [DOI] [PubMed] [Google Scholar]
- Twentyman P. R., Brown J. M., Gray J. W., Franko A. J., Scoles M. A., Kallman R. F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst. 1980 Mar;64(3):595–604. [PubMed] [Google Scholar]
- Twentyman P. R., Kallman R. F., Brown J. M. The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin. Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1255–1260. doi: 10.1016/0360-3016(79)90649-7. [DOI] [PubMed] [Google Scholar]
- Twentyman P. R. Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721. Br J Cancer. 1981 Jun;43(6):745–755. doi: 10.1038/bjc.1981.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wasserman T. H., Phillips T. L., Ross G., Kane L. J. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721. Cancer Clin Trials. 1981;4(1):3–6. [PubMed] [Google Scholar]
- Yuhas J. M. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res. 1980 May;40(5):1519–1524. [PubMed] [Google Scholar]
- Yuhas J. M., Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep. 1980 Jan;64(1):57–64. [PubMed] [Google Scholar]
- Yuhas J. M. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat Rep. 1979 Jun;63(6):971–976. [PubMed] [Google Scholar]
- Yuhas J. M., Spellman J. M., Jordan S. W., Pardini M. C., Afzal S. M., Culo F. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer. 1980 Oct;42(4):574–585. doi: 10.1038/bjc.1980.282. [DOI] [PMC free article] [PubMed] [Google Scholar]